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Rapidly progressive glomerulonephritis (RPGN) is character-
ized histologically by focal necrotizing glomerular lesions with
crescent formation, and clinically by the development of renal
failure within weeks or months. Although RPGN may be
associated with a variety of systemic diseases, or develop on a
background of primary glomerulonephritis, two distinct types
predominate in most nephrological practices. In one, which is
less common, there are autoantibodies to glomerular basement
membrane (GBM) which may also react with lung basement
membrane producing Goodpasture's syndrome, and in the
other there are autoantibodies to neutrophil cytoplasmic anti-
gens and clinicopathological features of small vessel vasculitis.
The latter type usually occurs in the context of Wegener's
granulomatosis (WG) or microscopic polyarteritis (MP), al-
though so-called idiopathic RPGN probably forms part of the
same spectrum of disease. We shall consider separately what is
known of autoimmunity to glomerular antigens in these two
disorders, although it has recently been recognized that both
immune mechanisms may sometimes co-exist.
Autoimmunity to glomerular basement membrane in
Goodpasture's syndrome
Goodpasture's syndrome is the term used to describe the
combination of severe glomerulonephritis and lung hemorrhage
[1, 2]. Various immunopathological processes, including sys-
temic vasculitis, are responsible for the clinical picture but now
the eponym is usually reserved for cases with detectable
antibodies to glomerular basement membrane [3]. It is also
apparent that an identical form of antibody-mediated glomeru-
lonephritis can occur with or without lung hemorrhage, and
thus the term "anti-GBM disease" is appropriate in either
circumstance [41.
The nephrotoxicity of heterologous antibodies raised to kid-
ney homogenates had been appreciated in experimental animals
since 1900 [5], but it was not until the 1950s that the GBM was
demonstrated to be the source of the nephritogenic antigen [6].
The development of immunofluorescence microscopy allowed
the demonstration of linear deposition of immunoglobulin along
the GBM in nephrotoxic nephritis [7], and similar findings were
soon reported in renal tissue of patients with Goodpasture's
syndrome [8, 9]. The pathogenicity of these autoantibodies was
subsequently demonstrated by transfer experiments in which
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antibody eluted from diseased kidneys could be used to induce
nephritis in monkeys [10].
The glomerulonephritis of anti-GBM disease pursues a char-
acteristically rapid course, and light microscopy generally re-
veals a high proportion of crescents [11]. Although the mecha-
nism of crescent formation is not fully understood, recent
ultrastructural studies suggest that necrosis of the GBM is the
common underlying abnormality [12]. Pulmonary hemorrhage
occurs in 50 to 90% of patients in different series [4], and is
much more common in those who smoke cigarettes [13]. The
prognosis of untreated patients was poor, and the improved
outlook following therapy with plasma exchange and immuno-
suppressive drugs provides further evidence for the pathoge-
nicity of anti-GBM antibodies [14]. Only exceptionally do
patients who are dialysis-dependent at presentation recover
worthwhile renal function despite adequate control of anti-
GBM antibody production.
Diagnosis and monitoring
The demonstration of linear deposits of IgG on the GBM by
direct immunofluorescence (IF) of renal biopsy material has
been the standard way of confirming the diagnosis since the late
1950's, but there are now several reliable assays for detection of
circulating anti-GBM antibodies. These include radioimmu-
noassays (RIA) [15—17] and enzyme-linked immunosorbent
assays (ELISA) [18, 19], which are more sensitive than indirect
immunofluorescence techniques, and are almost completely
specific for anti-GBM disease [15]. These assays depend upon
the reactivity of autoantibodies with soluble glycoprotein re-
leased from GBM by collagenase.
The assay has been of great diagnostic value, and has also
proved useful in the monitoring of treatment. Reduction in the
concentration of circulating antibody parallels clinical improve-
ment, and once antibody has become undetectable immunosup-
pressive treatment can generally be discontinued [20, 21]. Our
RIA detects only binding of IgO to the GBM, whereas direct
fluorescence may detect other antibody isotypes. Although
uncommon, binding of both IgA and 1gM anti-GBM antibodies
has been recorded [14], and recent studies [22, 23] indicate that
the autoimmune response is often restricted to IgGi and IgG4
subclasses. In one report [22], recurrence of an IgGi antibody
was associated with clinical disease, whereas that of an IgG4
antibody was not.
Production of monoclonal antibody (P1) to GBM
The reactivity of human autoantibodies with collagenase-
digested GBM in the RIA demonstrated that the autoantigen
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was present in this preparation and so attempts have been made
using this material to obtain a monoclonal antibody reactive
with the Goodpasture antigen (GA). Mice were immunized with
the collagenase digest of human GBM and spleen cells from a
responsive animal were fused with mouse myeloma NS1.
Hybridomas were screened by ELISA for anti-GBM activity
and the positives cloned by limiting dilution; reactivity of
antibody from positive clones was confirmed by indirect IF on
normal human kidney. One such monoclonal (P1) reacted
strongly with GBM in solid phase assays, and showed a similar
pattern of binding to GBM and tubular basement membrane
(TBM) as did autoantibody eluted from patients' kidneys [24].
This reagent has been used subsequently in studies of the
autoantigen in Goodpasture's syndrome [25, 26].
Distribution of the Goodpasture antigen
Direct IF of tissue from patients with anti-GBM disease
almost invariably demonstrates IgG deposition along the GBM,
and less frequently there are deposits along certain (but not all)
TBM [3, 4, 27]. Adequate demonstration of IgG on the alveolar
basement membrane is technically more difficult, but both focal
and diffuse linear deposits have been reported in affected lung
[3, 28, 29]. Rarely, IgG has been reported on choroid plexus
basement membrane [26, 27, 301 and on basement membranes
of the retinalchoroid of the eye [31]; binding in all these sites has
been reported in a single patient [26]. There have been very few
studies of the ultrastructural localization of antibodies to GA in
the GBM, because adequate fixation for electron microscopy
tends to destroy antigenicity. One report, which has yet to be
confirmed, suggests that GA is present mainly in the lamina rara
interna [32].
The distribution of immunoreactive Goodpasture antigen in
normal human tissue has been studied using monoclonal P1,
autoantibody eluted from patients' kidneys (GE) and antibody
eluted from the kidneys of sheep with Steblay nephritis (SE)
[25, 261. The pattern of binding was the same with all three
reagents. There was strong linear binding to GBM and weaker,
but consistent, binding to Bowman's capsule. Only certain
tubular basement membranes showed linear staining by IF, and
these were shown to have the characteristics of distal tubules
when studied by immunoperoxidase techniques. There was
linear binding to both alveolar and choroid plexus basement
membranes, as expected, and also to basement membranes
within the eye. Of additional interest, there was binding to sites
in the cochlea, thyroid, adrenal, pituitary, breast and liver, but
not in other organs studied (Table 1).
Previously [33], differences have been reported in the binding
pattern of anti-GBM antibodies eluted from the kidneys of
different patients. In particular, eluates from cases of Good-
pasture's syndrome bound more frequently to extraglomerular
sites than did those from patients with nephritis only. However,
all four patients' eluates in our study bound in the same pattern
as Steblay eluate and the monoclonal P1. We were also unable
to confirm, using all three types of antibody, a report [34] that
GA was detectable in skin and placenta after denaturation with
6 M urea at pH 3.5. In this connection, however, immunoblot-
ting studies have demonstrated the presence of GA in collage-
nase digests of placental basement membrane [351.
Co-localization experiments, using double immunofluores-
cence, confirmed identical binding of Goodpasture eluate, Ste-
Table 1. Reactivity of monoclonal P1, Goodpasture eluate and
Steblay eluate with human extraglomerular basement membranes
distal tubule, loop of Henle
and collecting duct
alveolar basement membrane
basement membrane of
choroidal epithelium
choroid, ciliary body, Bruch's
membrane and lens capsule
ducts
hepatic arteries within portal
tract
follicular basement membrane
Negative
Placenta Cervix
Skin Endometnum
Spleen Umbilical cord
Small intestine Prostate
Stomach Renal and carotid arteries
Submandibular gland Pancreas
Note: Data are from reference [26]. Monoclonal P1 also bound to
membranes in the cochlea [25].
blay eluate, and P1 on normal human tissues. Further co-
localization studies have been performed to compare the distri-
bution of GA with that of type IV collagen, using appropriate
combinations of Goodpasture and Steblay eluates and P1 to-
gether with a mouse monoclonal (PHM12), and a polyclonal
guinea-pig anti-serum to human type IV collagen. The various
antibodies to the GA bound only where type IV collagen was
found, but the distribution of type IV was much more exten-
sive. In the kidney, anti-type IV collagen antibodies bound to
GBM, Bowman's capsule, all TBM, mesangial matrix and
vascular basement membranes (Fig. 1).
These observations permit a number of conclusions to be
drawn about the autoimmune response in Goodpasture's syn-
drome. Since the pattern of binding of several autoantibodies
was identical to that of P1 and SE, it seems reasonable that all
reacted with the same antigen. Furthermore, if the monoclonal
antibody P1 recognizes one antigenic determinant, as should be
the case, then the same autoantigen must be present in the
different organs affected in Goodpasture's syndrome, notably
kidney and lung. Factors other than the reactivity of the
autoantibody may therefore determine the clinical features of
the disease. One explanation, with some experimental support
[36, 37], is that factors which increase alveolar capillary per-
meability may allow penetration of antibody to the basement
membrane. The effects of cigarette smoking [13] and intercur-
rent infection [381, which may provoke lung hemorrhage in
patients, could act, at least in part, by this mechanism.
The presence of immunoreactive GA in the lens capsule,
Bruch's membrane of the retina, and the cochlea provides
further indirect evidence that a single autoantigen is involved in
Goodpasture's syndrome. This deduction is based on the fact
that patients with Alport's syndrome, a form of hereditary
nephritis [39], may demonstrate: (i) lenticonus, macular flecks
and nerve deafness; (ii) impaired reactivity of GBM with
anti-GBM antibodies [40, 411. The second point has been
confirmed by studies [42, 43] using P1 as well as GE to show
Positive
Kidney
Lung
Choroid plexus
Eye
Breast
Liver
Thyroid
Pituitary
Adrenal
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Fig. 1. Double immunofluorescence of kidney showing more widespread distribution of type IV collagen than of Goodpasture antigen, as
demonstrated by binding of(A) monoclonal P1 and (B) guinea-pig anti-type IV collagen. Photos are courtesy of Mr. S.J. Cashman.
that patients with Alport's syndrome have reduced or absent
binding of anti-GBM antibody in the kidney; other organs have
not yet been examined. The pattern of organ involvement in
Alport's syndrome may therefore be due to an inherited abnor-
niality of a single molecule related to the Goodpasture antigen.
Finally, there is increasing evidence that GA is contained
within the non-collagenous domain (NC1) of type IV collagen.
If this is the case, then the double immunofluorescence studies
suggest that GA is not an integral part of the type IV collagen
molecule, or (more likely) that type IV collagen is heterogenous
in its primary sequence or three-dimensional structure [26].
Immunochemistry of the Goodpasture antigen
Despite considerable advances in the understanding of the
biochemistry of the GBM [44, 45], the precise molecular
structure of the GA remains unknown [461. However, there is
good evidence that it is contained within one of the non-
collagenous domains of the type IV collagen molecule [47, 48].
Type IV collagen forms a network within GBM which is built up
from type IV monomers. Each of these consists of a rod-like
triple helix with a globular domain (NC 1) at the C-terminal end.
The triple helix is composed of parallel pro-collagen chains,
probably two al(IV) and one a2(IV) molecules [451. Adjacent
triple helical molecules bind to each other at the globular
domain, so that a hexameric NC1 complex is produced after
collagenase digestion. The primary sequence of both al(IV) and
a2(IV) chains, including the NC! domain, is now known [49,
50].
This information must be related to immunochemical studies
of the GA. When collagenase-digested GBM is run on an SDS
polyacrylamide gel, a number of components can be detected
by standard protein stains. Separated GBM can be transferred
to nitrocellulose sheets and overlaid with anti-GBM antibodies
(Western blotting) to identify the components containing GA.
Several studies of this type have been reported [25, 35, 5 1—53]
using human autoantibodies. The results show that GA can be
detected in a small number of bands (not more than 6) between
approximately 26 and 58 kD in molecular weight. These obser-
vations cannot exclude the possibility that several autoantigens
are involved in Goodpasture's syndrome, and so this problem
was addressed using the monoclonal P1 [25].
In these experiments, collagenase-solubilized GBM, as used
in the RIA, was run in a 5 to 20% gradient SDS polyacrylamide
gel and transferred to nitrocellulose sheets. These were overlaid
with monoclonal P1 or with sera from patients with anti-GBM
disease, and the binding detected with appropriate radiolabelled
secondary reagents followed by autoradiography. Blocking
studies were also performed, in which an excess of human
anti-GBM antibody was pre-incubated on the nitrocellulose
sheets before addition of P1, or alternatively P1 was added
before human autoantibody. Sera from all 42 patients studied
bound to the same components of GBM, between 26 and 58 kD,
as did monoclonal P1. Furthermore, pre-incubation with sera
from eight of eight patients blocked the subsequent binding of
P1; densitometer scanning of the autoradiographs quantified
inhibition of binding at 83 to 89%. Similarly, pre-incubation
with P1 blocked the subsequent binding of IgG from six of six
patients' sera by 58 to 89%.
The recognition by monoclonal P1 of the same six bands
which were recognized by autoantibodies from different pa-
p -.i.
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tients (with and without lung hemorrhage) confirms that a single
antigen is the target of the autoimmune response, and that it is
present on fragments of different molecular weight in denatured
GBM. The blocking experiments demonstrate that the same (or
a very closely related) epitope is recognized by both P1 and
several human autoantibodies; the autoimmune response is
therefore highly restricted in its specificity. In addition, this
observation validates the use of P1 in attempts to isolate the
antigen by immunoaffinity chromatography.
There is, however, a report in which the heterogeneity of
nephritogenic antigens was studied by 2-D gel electrophoresis
of human GBM followed by Western blotting with patients' sera
[54]. The authors found that staining patterns were similar with
all autoantibodies, which bound predominantly to cationic
components, but that certain sera (3 of 10) reacted more
strongly with additional neutral components. Differences in
charge, avidity or concentration of the antibodies could account
for this finding, as well as the postulated heterogeneity of the
antigen. In addition, serum from a case of anti-GBM disease
following transplantation bound in a different pattern, which
could be due to alloreactivity. A further study from the same
group demonstrated broad similarities in the binding pattern of
anti-GBM antibodies to components of GBM from different
species, although only human GBM contained a very cationic
monomer (M28) thought to represent the GA [55].
There is general agreement that the GA is associated with the
NC1 domain of type IV collagen, and that it is unlikely to be
part of other recognised components of GBM. The work of
Wieslander and of Butkowski [47, 48, 56, 57] provides most
evidence that GA is localized to the NC1 domain. They
demonstrated the reactivity of human anti-GBM antibodies
with non-collagenous polypeptides isolated from bovine GBM,
and noted the monomer-dimer relationship of these molecules
in denaturing conditions. The monomeric form was chemically
equivalent to collagenase-resistant products of type IV a
chains, suggesting that monomeric and dimeric subunits of the
NC1 hexamer of type IV collagen contained the GA. Further
resolution of these polypeptides using reversed phase HPLC
and SDS-gel electrophoresis revealed that one set of mono-
meric and related dimeric components, termed M2 and D2,
were immunoreactive whereas others were not. There was also
cross reactivity of antibodies raised to type IV collagen a chains
with M2, and vice versa.
Physicochemical studies subsequently revealed that the NCI
hexamer, although not itself reactive with anti-GBM antibodies,
could be dissociated by guanidine HCL or acetic acid to form
monomers and dimers, and hence expose the antigenic sites
[56]. The precise molecular structure of the bovine equivalent
of GA, however, remains elusive. One recent study [57] re-
ported amino-terminal amino-acid sequence data on various
monomeric peptides from NC1 of bovine lens. Ml was found to
correspond to the non-collagenous segments of al and a2
chains of type IV collagen; M2 (containing the GA) and M3 had
distinctive sequences but each had Gly-X-Y triplets, suggesting
a collagen chain origin. The authors concluded that these
represented novel chains of basement membrane collagen,
which may be part of type IV or a new species of collagen.
Although the above studies were performed on bovine mate-
rial, the same group has recently reported similar findings using
human GBM [58]. In these experiments GBM was solubilized
by collagenase and purified by ion exchange, gel filtration and
reversed phase HPLC. A similar range of monomers and dimers
was identified as from bovine material, and again only M2 was
found to be reactive with human anti-GBM antibodies. It is,
however, difficult to reconcile this observation with the results
from other groups, which show that at least two components in
the monomeric size range are immunoreactive. Differences in
the preparation of antigen, reaction conditions, or characteris-
tics of the antibodies used could be responsible.
Concluding remarks
Goodpasture's syndrome is now one of the best characterized
autoimmune diseases in man. Anti-GBM autoantibodies have
been shown to be pathogenic, although direct T cell-mediated
immunity may also be important and this possibility requires
further investigation. The detection of anti-GBM antibodies is
of proven value in the diagnosis and monitoring of this disease,
and has contributed to the development of effective though
non-specific treatment. The mechanisms of induction of autoim-
munity have also been explored in this disorder, and the role of
both genetic and environmental factors has been clearly dem-
onstrated [4]. In particular, there is a strong association of the
disease with major histocompatability class II antigen HLA-
DR2 [59], and it is possible that various environmental stimuli
(such as infection or toxic agents) may expose or alter the GA
to render it immunogenic in susceptible individuals. Alterna-
tively, the disease could result from a breakdown in normal
immunoregulatory mechanisms. These possibilities are consid-
ered in more detail elsewhere in this issue. The molecular basis
for the autoimmune response to GBM is still under investiga-
tion, but both the restricting MHC class II gene product and the
autoantigen should soon be characterized. This level of under-
standing should lead on to the development of specific immu-
notherapeutic strategies for anti-GBM disease, which may be
widely applicable in human autoimmunity.
Autoimmune responses in the RPGN associated with systemic
vasculitis
Systemic vasculitis is the term used to describe a variety of
clinicopathological syndromes which have in common inflam-
mation and necrosis of blood vessels at various sites throughout
the body [60, 61]. The process may arise as a primary event and
be restricted to blood vessels or it may occur secondary to
diseases such as rheumatoid arthritis, cryoglobulinemia or atrial
myxoma. The primary vasculitic syndromes can be classified
according to the size of vessel affected and presence or absence
of granulomata (Table 2) [62]. Renal involvement is most
commonly found in primary small vessel vasculitides, such as
microscopic polyarteritis or Wegener's granulomatosis which,
although perhaps indolent at first, can readily undergo a rapidly
progressive phase. Biopsy at this stage frequently shows a focal
segmental necrotizing glomerulonephritis with crescents, indis-
tinguishable histologically from that found in anti-GBM disease.
However, the evidence that similar autoimmune mechanisms
are operating in the development of RPGN associated with
systemic vasculitis is not substantial. Immune deposits in the
glomeruli are not commonly found in systemic vasculitis
whereas linear deposits of IgG are the rule in anti-GBM disease
[4, 60, 61]. Furthermore, anti-GBM autoantibody has been
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Table 2. Classification of systemic vasculitides
Vessel Size With granulomata Without granulomata
Large
Medium
Small
Takayasu's arteritis
Churg-Strauss disease
Wegener' s granulomatosis
Temporal arteritis
Polyarteritis nodosa
Henoch-SchOnlein purpura
Microscopic polyarteritis
Kawasaki disease
eluted from such renal tissue and its pathogenicity demon-
strated by transfer experiments [101. Circulating immune com-
plexes (putatively phlogistic if trapped in glomerular capillary
walls) are detectable in some patients with systemic vasculitis
but, unlike anti-GBM antibody, bear little relationship to the
presence of immune deposits in the kidney. Perhaps the most
attractive evidence to support an autoimmune aetiology has
come from studies of treatment. Striking responses to cytotoxic
drugs, particularly cyclophosphamide, and steroids have been
reported in patients with systemic vasculitis and nephritis, even
where renal disease is severe [61, 63]. Furthermore, plasma
exchange has been found to confer additional benefit to drug
treatment in patients with severe nephritis in a prospective
controlled trial, thereby providing a clue that circulating hu-
moral factors might be important in pathogenesis [64]. Much
interest was provoked, therefore, when reports appeared that
certain patients with systemic vasculitis had circulating auto-
antibodies to neutrophil cytoplasm antigens (ANCA) and that
their levels fluctuated with disease activity [65].
Antibodies to neutrophil cytoplasm antigens
Antibodies specific for neutrophil cytoplasm were first de-
scribed in patients with diseases consistent with systemic
vasculitis and necrotizing glomerulonephritis in the early 1980s
[66, 67]. However, their significance as diagnostic markers was
only appreciated when Van der Woude showed that they could
be detected in a large number of patients with WG [65]. Since
titers correlated with disease activity it appeared that levels
might be useful in monitoring treatment. This led to the devel-
opment of a range of assays for these antibodies, so that their
specificity for vasculitis could be examined, and also to efforts
to try to identify the nature of the autoantigens.
Assays for anti-neutrophil cytoplasmic antibodies
Indirect immunofluorescence tests for ANCA have now been
established in many centers, and a standardized technique was
agreed at an International Workshop on ANCA in Copenhagen,
in January 1988 [68]. In brief, this involved separation of normal
human neutrophils from heparinized blood by layering over a
1.25% methyl cellulose 13% hypaque gradient. The cells were
then washed with a neutral buffer containing protein (for
example, phosphate buffered saline/l% human serum albumin)
and attached to microscope slides in a cytocentrifuge. Fixation
was by incubation for five minutes with prechilled absolute
ethanol at 4°C. Thereafter the slides could be stored for up to
one week at 4°C before use. Standard indirect IF methods were
then employed (30 to 60 mm at room temperature with test or
control sera diluted 1/16, followed by a similar incubation with
fluoresceinated anti-human IgG to detect specific antibody
binding). The typical immunofluorescence pattern produced by
WG sera showed a coarsely granular appearance in the cyto-
plasm (accentuated nearer to the center of the cell where the
vertical diameter was greater), but no binding to the multilobed
nucleus was apparent. Binding also occurred to the cytoplasm
of monocytes, but not lymphocytes.
Radioimmunoassay [69, 70] and ELISA [71] solid phase
assay systems have now been developed to allow objective
detection and quantitation of AN CA. Our RIA uses as ligand an
acid extract of sonicated normal human neutrophils. Binding of
autoantibodies in test sera is detected by a radio-labelled
antihuman globulin. This proved to be an order of magnitude
more sensitive than indirect immunofluorescence.
Modification of the assay to incorporate an inhibition stage
(by pre-incubation with soluble antigen or control protein)
demonstrated specificity of the antibody binding activity. This
was of particular use when results were close to background
and possibly elevated due to non-specific stickiness of some
sera, for example in systemic lupus erythematosus (SLE).
Substitution of class (and subclass) specific antisera allowed
detection of different isotypes of autoantibody immunoglobulin,
and led to definition of subgroups of patients restricted in their
autoantibody class; those restrictions, in turn, appeared to be
associated with particular clinical features [72].
Use of ANCA assays for diagnosis
The use of assays for ANCA has shown that they can be
detected in patients with MP as well as those with WG;
although the fine specificity for neutrophil antigens may be
different [691. Other closely related vasculitides such as Churg-
Strauss syndrome [73, C.M. Lockwood and C.D. Pusey, un-
published observations) and idiopathic RPGN (C.M. Lockwood
and C.O.S. Savage, unpublished observations) have also been
characterized by presence of ANCA, whereas patients with
granulomatous disorders, such as tuberculosis or sarcoid, or
inflammatory lung disease, such as fibrosing alveolitis, do not
possess these antibodies. Patients with primary glomerular
disease, such as membranous or mesangiocapillary glomerulo-
nephritis, are also negative. Rarely, patients with rheumatoid
arthritis or SLE give false positive results, which on further
investigation using the RIA inhibition test, have shown that the
binding was not specific [691.
In an attempt to ascertain the value of ANCA in the diagnosis
of WG or MP, we combined both indirect immunofluorescence
and radioimmunoassays to conduct a prospective double blind
study of their sensitivity and specificity [70]. Serum samples
from 100 consecutive patients in renal units throughout the UK,
with a putative diagnosis of RPGN, were tested by indirect IF
and RIA with inhibition studies. Clinical data were obtained by
postal questionnaire and analyzed by a physician experienced
in the management of vasculitis, but who was unaware of the
laboratory findings. The patients were assigned to four groups.
These consisted of: (i) those whose diagnosis was untreated
primary systemic vasculitis (either WG or MP); (ii) those with
primary systemic vasculitis (WG or MP) but treated or inactive;
(iii) other forms of systemic vasculitis (such as, Henoch-
SchOnlein purpura); (iv) patients not thought to have primary
systemic vasculitis. Twenty-two of 23 patients in the first group
were positive in both assays. Eight of 17 patients in the second
group were positive in the RIA (five of these also being positive
by hF); presumably this reflects the effect of treatment in
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reducing antibody levels. None of the six patients in the third
group were positive. In the fourth group, 52 of 54 patients did
not have ANCA, and of the two patients who were positive in
both ANCA assays, one had idiopathic RPGN and the other
had an undefined systemic illness with eosinophilia. Thus when
results for both assays were combined, assays for ANCA had a
specificity and a sensitivity of 96% for the diagnosis of WG and
MP.
Evidence is accumulating from long-term follow-up studies
that these assays are useful for monitoring progress. In our own
practice, none of the patients who have become ANCA nega-
tive and remained so have relapsed. Patients who have relapsed
have all been ANCA positive, and in a number of them a rise in
ANCA titers preceded the recurrence of clinical symptoms.
Subgroups of patients with anti-neutrophil cytoplasm
antibodies
(a) Children. Crescentic glomerulonephritis is a rare cause of
renal failure in children, and when severe (crescents in at least
80% glomeruli) is usually associated with RPGN. Pediatric
patients with RPGN have been screened for ANCA [74], and
ANCA was identified in three of 10 cases of severe crescentic
RPGN; one of these had clinicopathological evidence of Wege-
ner's, while the other two had isolated idiopathic RPGN.
(b) Pulmonary-renal syndrome associated with 1gM ANCA.
The use of class-specific antisera in the RIA for ANCA identi-
fied a small group of patients characterized as having 1gM class
ANCA (without IgG) at presentation. Eight such patients have
been reported, all with pulmonary hemorrhage which was
severe enough to require assisted ventilation in five patients.
Seven of the eight also had renal involvement and four required
dialysis. None of the patients had circulating anti-GBM anti-
bodies. Renal biopsy performed in six showed crescent forma-
tion in five patients; in the other patient renal tissue obtained
later at autopsy showed normal glomeruli by light microscopy.
Immunofluorescence examination of the biopsies showed that
there were glomerular immunoglobulin deposits in four of the
six; all four showed granular IgG and 1gM in capillary loops and
two of four also had 1gM deposits in vessels. In the one patient
whose renal tissue was available at autopsy, immunoglobulins
were eluted which showed specific binding in the RIA for
ANCA. Clinical involvement of other organs in these patients
was minimal, being confined to rash in two, arthralgia in two
and sinusitis in one. Half the patients died, three of uncon-
trolled disease shortly after referral and one from a myocardial
infarction which occurred two weeks after admission during
convalescence.
In three patients it was possible to obtain serial serum
samples during treatment. In all three the class of the autoan-
tibody immunoglobulin switched from 1gM to IgG, although this
was not associated with evidence of disease activity. If these
1gM autoantibodies are pathogenetically important, then the
use of plasma exchange as therapy is particularly appropriate as
1gM is predominantly restricted to the intravascular compart-
ment and unlike IgG has little extravascular distribution,
(c) Patients with anti-GBM disease. A search for ANCA was
conducted prospectively in patients who had circulating anti-
GBM antibodies detectable by RIA [75]. Serum samples from
890 consecutive patients suspected to have RPGN were ana-
lyzed; 246 (28%) were positive for ANCA alone, 47 (5%) were
positive for anti-GBM antibodies alone, while 20 (2%) were
positive for both ANCA and anti-GBM by RIA. The specificity
of the RIA was confirmed by specific inhibition in all 20 patients
and 18 were also positive by indirect immunofluorescence.
Furthermore, binding to neutrophil antigen in the RIA could be
inhibited by soluble neutrophil cytoplasmic antigen but not by
soluble GBM; similarly binding in the anti-GBM RIA could be
inhibited by soluble GBM and not by soluble neutrophil cyto-
plasmic antigen. Additional studies with Western blotting
showed that IgG in all 20 sera recognized GA.
Clinical and pathological information on the 20 patients was
obtained by questionnaire. The patients (11 male, 9 female)
ranged in age from 13 to 73 years. All had hematuria, and
although renal function was normal in three, the remainder had
raised creatinines, nine of these 17 being dialysis dependent.
Eighteen patients were biopsied and all showed crescentic
change (mean of 70% glomeruli involved with crescents), with
segmental necrosis in the capillary ioops. Granulomata were
seen in three biopsies although vasculitis was only seen in one.
Immunofluorescence of the renal biopsy was available from 15
patients: 12 of 15 had linear IgG on the GBM and one had linear
C3; the remaining two patients had no linear IgG but granular
1gM and C3 only. Deposits of complement in vessel walls were
noted in five patients. Evidence of pulmonary hemorrhage was
present in 13 (only two were habitual smokers). Other extra-
renal symptoms were not prominent but sinusitis was present in
5 patients and arthritis and a rash each occurred in two patients.
With treatment, three of the nine dialysis-dependent patients
regained independent renal function, which is not uncommon in
patients who have systemic vasculitis but is unusual in dialysis-
dependent patients with anti-GBM disease [4, 14, 63]. Two
patients have relapsed (pulmonary in one, and pulmonary and
renal in the other), and on both occasions ANCA were positive
but anti-GBM antibodies were not detectable.
Vasculitis associated with anti-GBM disease has been re-
ported before, seemingly in a small number of patients and
based on the histological appearances of biopsy material [4].
That up to one-third of patients with anti-GBM disease have
evidence of ANCA suggests that vasculitis may play a more
major role than was previously thought, although whether this
is cause or consequence of anti-GBM antibody-mediated injury
awaits further studies.
Specficities of ANCA: Search for autoantigens
The nature of the cytoplasmic antigens recognized in WG and
MP has been examined by fractionating the neutrophil acid
extract on a gel filtration column [69]. Material from normal
neutrophils reproducibly generated multiple components from
100 kD to 2 kD as measured by optical density of the fractions.
When these fractions were coated to microtiter plates, sera
from WG bound to three different fractions of approximately
100, 6 and 2 kD; sera from patients with MP appeared to bind
only to the 100 kD fragment. The 6 kD component was purified
and used to raise monoclonal antibodies, one of which, W8, was
used for further studies. The monoclonal W8 bound to the same
three fractions as did WG sera, suggesting that these autoanti-
bodies were recognizing a single determinant which was carried
on fractions of different molecular weight.
The observation of raised concentrations of alkaline phospha-
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tase in the sera from many patients with systemic vasculitis,
and the fact that this enzyme is a constituent of polymorpho-
nuclear leucocytes likely to be extractable by acid sonication,
raised the question whether this could be an autoantigen. Direct
binding and competitive inhibition studies, using calf alkaline
phosphatase, together with fluid phase immune complex forma-
tion between labelled alkaline phosphatase and vasculitic sera,
have supported this hypothesis [691, and similar results were
obtained using W8. This monoclonal was then used to examine
the location of the antigenic determinants in tissue sections.
Strong binding to vascular endothelial cells lining the lumen of
human arteries and arterioles suggested that determinants cross
reactive with those in polymorph cytoplasm were present there.
Further evidence for cross reactivity with glomerular antigen
has come from indirect immunofluorescence studies in which
W8 or F(ab)2 fragments of strongly positive ANCA-containing
sera showed binding to cultured glomerular cells with charac-
teristics of both epithelial and endothelial cells [761.
Biochemical characterization of the neutrophil autoantigen
has been attempted using purified 6 kD component, which was
then reduced and yielded a 2 kD component that was still
antigenic, thus far the smallest component recognized by Weg-
ener's sera. Amino acid sequencing of this fragment showed it
to be a decapeptide with strong amino acid sequence homology
with the published sequences of the "loop" region of human
placental and liver alkaline phosphatase. Neutrophil alkaline
phosphatase itself has not yet been sequenced.
Other researchers working with different preparations have
tried to localize the antigen to polymorph granules either alpha
(primary) or beta (secondary). Rasmussen, Boregaard and Wiik
[77] and Falk and Jennett [71] have isolated primary granules
and found that systemic vasculitis sera bound to these in
ELISA. Goldschmeding Ct al [78] and Wieslander [68] have
derived antigenic material from the alpha granules which, on
SDS-PAGE or by immunoprecipitation, runs with a molecular
weight of approximately 30 kD. By contrast, Gross, Ludemann
and Schroder have suggested that the antigen can be obtained
from neutrophils after treatment with phorbol ester, a chemical
which specifically releases secondary granules [79].
Recently, Falk and Jennett have shown that antibodies in
some vasculitic sera react with myeloperoxidase, another neu-
trophil enzyme, situated on the primary granules [71]. Sera
from 27 of 35 patients with diseases ranging from idiopathic
necrotizing glomerulonephritis (without extra-renal involve-
ment) to systemic vasculitis typical of Wegener's or polyarte-
ntis reacted with purified myeloperoxidase used as an antigen in
an ELISA or nitrocellulose dot-blot system.
At present the precise nature of the autoantigenic determi-
nant remains an enigma; it may be that patients with systemic
vasculitis have anti-neutrophil autoantibodies of more than one
specificity, or that the determinant recognized, such as the
"loop" region, is common to different molecules.
Concluding remarks
Autoantibodies to components of neutrophil cytoplasm have
come to be recognized as useful diagnostic markers for certain
patients whose RPGN is associated with systemic vasculitis.
Thus, for the first time, there is a sensitive laboratory test with
high specificity for these disorders which can alert physicians
for the need for treatment. This is the more important since
growing experience suggests that substantial recovery of renal
function can be obtained even in patients with severe renal
impairment at referral [63, 64]. How useful these laboratory
tests will be for monitoring patients during follow-up is as yet
unclear, although in some anecdotal reports they have proved
valuable. Whether ANCA are pathogenetically important is the
subject of speculation. That they are found in virtually all
patients with WG or MP argues for the fact that their generation
is a mechanism fundamental to the development of these forms
of systemic vasculitis. Better understanding of the pathogenesis
of these disorders will be forthcoming when the nature of the
antigenic target is determined at a molecular level.
Reprint requests to C.D. Pusey, M.R.C.P., Department of Medicine,
Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane
Road, London W12 ONN, England, United Kingdom.
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